Mark Cuban’s Cost‑Plus Drug Model Threatens the PBM Pricing Cartel
Mark Cuban explains how Cost Plus Drugs sells generics at cost + 15%, cutting out middlemen and exposing hidden fees. The model forces pharmacy‑benefit managers to rethink opaque pricing, promising lower costs for patients and a shake‑up of the U.S. drug‑distribution market.